Market Place
Sourcing Support
Aldeyra Announces FDA Review of Reproxalap for Dry Eye Disease
18 Nov 2024 //
BUSINESSWIRE
Aldeyra Therapeutics to Participate in Jefferies London Conference
14 Nov 2024 //
BUSINESSWIRE
Aldeyra Therapeutics to Present at Disruptive Innovations Symposium
31 Oct 2024 //
BUSINESSWIRE
Aldeyra Files New Reproxalap Application For Dry Eye Disease
03 Oct 2024 //
BUSINESSWIRE
Aldeyra Therapeutics to Join H.C. Wainwright Annual Global Investment Conference
05 Sep 2024 //
BUSINESSWIRE
Aldeyra Therapeutics Achieves Primary Endpoint In Dry Eye Disease Trial
08 Aug 2024 //
BUSINESSWIRE
Aldeyra Schedules Call For Phase 3 Dry Eye Trial Results Of Reproxalap
07 Aug 2024 //
BUSINESSWIRE
Aldeyra Advances RASP Modulators, Shares Obesity Data At Investor Roundtable
20 Jun 2024 //
BUSINESSWIRE
Aldeyra Completes Enrollment In Phase 3 Reproxalap Dry Eye Disease Trial
13 Jun 2024 //
BUSINESSWIRE
Aldeyra Therapeutics to Host Investor Roundtable Q&A
12 Jun 2024 //
BUSINESSWIRE
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conf
29 May 2024 //
BUSINESSWIRE
Aldeyra Therapeutics: Phase 3 Trial for Reproxalap in Dry Eye
08 May 2024 //
BUSINESSWIRE
Aldeyra Highlights Preclinical Data, Announces Pivotal RP Trial Plan
25 Apr 2024 //
BUSINESSWIRE
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
18 Apr 2024 //
BUSINESSWIRE
Aldeyra Therapeutics Provides Clinical and Regulatory Update
04 Jan 2024 //
BUSINESSWIRE
ADC Tx, Aldeyra leave programs behind in 2023
04 Jan 2024 //
FIERCE BIOTECH
Aldeyra Therapeutics` skin disease drug succeeds in mid-stage study
19 Dec 2023 //
REUTERS
Aldeyra Therapeutics Schedules Conference Call and Webcast
18 Dec 2023 //
BUSINESSWIRE
Aldeyra Receives CRL from FDA for the Reproxalap NDA for Dry Eye Disease
28 Nov 2023 //
BUSINESSWIRE
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie
01 Nov 2023 //
BUSINESSWIRE
AbbVie seeks Restasis follow-up with small option fee for Aldeyra’s eye drops
01 Nov 2023 //
ENDPTS
Aldeyra sinks after FDA finds `substantive` issues in dry-eye disease filing
17 Oct 2023 //
ENDPTS
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
06 Jul 2023 //
BUSINESSWIRE
Aldeyra Announces Improvement from Baseline in Retinal in Ph2 Trial of ADX?2191
29 Jun 2023 //
BUSINESSWIRE
Aldeyra eyes trial in retinitis pigmentosa after small open-label readout
29 Jun 2023 //
ENDPTS
Aldeyra Schedules Conference Call Phase 2 Clinical Trial of ADX-2191
28 Jun 2023 //
BUSINESSWIRE
Aldeyra`s roller coaster June ends with positive ph. 2 data
28 Jun 2023 //
FIERCE BIOTECH
Aldeyra Announces Significant Reduction in Cough Frequency Ph2 Trial of ADX?629
27 Jun 2023 //
BUSINESSWIRE
Aldeyra Schedules Conference to Announce Results from PII Trial of ADX?629
26 Jun 2023 //
BUSINESSWIRE
FDA Issues Complete Response Letter to NDA for ADX-2191
22 Jun 2023 //
ONCLIVE
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
21 Jun 2023 //
BUSINESSWIRE
Aldeyra Therapeutics eye treatment meets late-stage study main goal
16 Jun 2023 //
REUTERS
Aldeyra Schedules Conference to Announce Results from Phase 3 INVIGORATE?2 Trial
14 Jun 2023 //
BUSINESSWIRE
Aldeyra to Participate in Fireside Chat at the Jefferies Healthcare Conference
02 Jun 2023 //
BUSINESSWIRE
Aldeyra Therapeutics Reports 1Q 2023 FYR & Recent Corporate Highlights
04 May 2023 //
BUSINESSWIRE
Aldeyra Completes Enrollment in Phase 3 Trial in Allergic Conjunctivitis
13 Apr 2023 //
BUSINESSWIRE
Aldeyra Enrolls First Patient in Phase 2 Trial of ADX-629 in Atopic Dermatitis
06 Apr 2023 //
BUSINESSWIRE
Aldeyra Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629
30 Mar 2023 //
BUSINESSWIRE
Aldeyra Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX?2191
16 Mar 2023 //
BUSINESSWIRE
Aldeyra Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
09 Mar 2023 //
BUSINESSWIRE
FDA Accepts for Priority Review ADX-2191 New Drug Application
02 Mar 2023 //
BUSINESSWIRE
Aldeyra Schedules Conference to Report Full-Year 2022 Financial Results
01 Mar 2023 //
BUSINESSWIRE
Aldeyra Announces Positive Results from 12-Month Safety Trial of Reproxalap
28 Feb 2023 //
BUSINESSWIRE
Aldeyra initiates Phase II clinical trials of ADX?629
17 Feb 2023 //
CLINICAL TRIALS ARENA
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Conference
09 Feb 2023 //
BUSINESSWIRE
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round
07 Feb 2023 //
BUSINESSWIRE
Aldeyra’s sights set on November PDUFA; Synbio startup scores cash
07 Feb 2023 //
ENDPTS
Aldeyra Therapeutics sNDA to the U.S. Food and Drug Administration for ADX?2191
21 Dec 2022 //
BUSINESSWIRE
Aldeyra’s ADX-629 Improved Signs of Intoxication in Alcohol Challenge PII Trial
13 Dec 2022 //
BUSINESSWIRE
Aldeyra Announces Positive Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
01 Dec 2022 //
BUSINESSWIRE
Aldeyra Therapeutics Submits NDA to the U.S. FDA for Reproxalap
29 Nov 2022 //
BUSINESSWIRE
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results
10 Nov 2022 //
BUSINESSWIRE
Aldeyra Schedules Webcast to Report Third-Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at Meeting
26 Oct 2022 //
BUSINESSWIRE
Aldeyra touts first part of PhIII for rare eye disease
07 Oct 2022 //
ENPTS
Aldeyra Schedules Conference to Announce Results from PIII Trial of ADX-2191
05 Oct 2022 //
BUSINESSWIRE
Aldeyra spies FDA filing ahead for dry eye drug reproxalap
15 Sep 2022 //
PHARMAPHORUM
Aldeyra Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA
14 Sep 2022 //
BUSINESSWIRE
